Sangamo Therapeutics announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry Disease

Presentation

Process and Platform Development for Production and Purification of CNS-Tropic Engineered AAV Capsids

Download PDF